WINNIPEG, MANITOBA--(Marketwired - April 26, 2013) -Miraculins Inc. (TSX VENTURE:MOM) ("Miraculins" or the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, today reported its results from operations for the quarter ended February 28, 2013.

Financial Results

With the commercial rollout of the Company's PreVu Non-Invasive Skin Cholesterol Test technology during the first quarter of fiscal 2013, Miraculins earned its first commercial revenue from the PreVu technology totaling $31,520. Additionally, the Company earned license fee revenues for the three months ended February 28, 2013 of $24,990 (2012 - nil) and recognized collaborative research and option fee income of $11,655 (2012 - $31,575).

Net loss for the quarter was $660,532 or $0.01 per share, compared to net loss of $548,258 or $0.01 per share in the same quarter a year ago and a net loss of $797,329 or $0.01 for the previous quarter. The net loss primarily relates to costs associated with the advancement of the Company's PreVu technology.

At February 28, 2013, the Company had cash totalling $368,996 compared to $911,808 as of November 30, 2012. Cash flows used in operating activities for the three months ended February 28, 2013 were $494,879, compared to cash flows used in operating activities of $311,458 for the three months ended February 29, 2012. On April 8, 2013, the Company announced the closing of a private placement offering with aggregate gross proceeds to the Company of $1,050,950 with the net proceeds being used for general corporate purposes including sales and marketing costs related to the Company's PreVu program.

About Miraculins Inc.

Miraculins is a medical diagnostic company focused on acquiring, developing and commercializing non-invasive tests for unmet clinical needs. A significant number of promising diagnostic opportunities remain un-commercialized because of the sizable gap between the discovery stage, when research institutions are typically involved, and the commercialization stage, when the larger commercial enterprises become interested. Miraculins has direct experience in bridging this gap. The Company's PreVu^® technology is a revolutionary new coronary artery disease risk assessment technology that measures cholesterol levels in a patient's skin non-invasively, painlessly and without the need for fasting. Miraculins is also advancing a suite of biomarkers to aid in the early detection of the devastating disease of pregnancy known as preeclampsia. The lead marker in the Company's preeclampsia program is partnered with Alere Inc., one of the world's largest diagnostic companies.

The Company recently announced that it has signed a non-binding term sheet with VeraLight, Inc. to acquire all assets related to the SCOUT DS^® technology, a groundbreaking diabetes screening technology that non-invasively measures changes in a person's skin indicative of prediabetes and type 2 diabetes, enabling cost-effective, easily accessible screening of those at risk.

For more information visit [ www.miraculins.com ].

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements include statements regarding the execution of definitive documentation and completion of the transaction. These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Miraculins' early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Miraculins' filings with Canadian securities regulatory authorities, as well as Miraculins' ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release. Miraculins cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Miraculins' forward-looking statements to make decisions with respect to Miraculins investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Miraculins cannot provide assurance that actual results will be consistent with these forward-looking statements. Miraculins undertakes no obligation to update or revise any forward-looking statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contributing Sources

Market Wire

N@N

Miraculins Reports First Quarter Financial Results for Fiscal 2013

Miraculins Reports First Quarter Financial Results for Fiscal 2013